Literature DB >> 31028196

Co-localization of Coagulation Factor X and its Inhibitory System, PZ/ZPI, in Human Endometrial Cancer Tissue.

Ewa Sierko1,2, Ewa Zabrocka3, Krystyna Ostrowska-Cichocka4, Piotr Tokajuk5,4, Lech Zimnoch6, Marek Z Wojtukiewicz5,4.   

Abstract

BACKGROUND/AIM: Hemostatic system components contribute to cancer progression independently from their roles in hemostasis. It has been shown that protein Z (PZ)/protein Z-dependent protease inhibitor (ZPI) inhibit coagulation factor X (FX). The aim of the study was to analyze the expression of PZ/ZPI in relation to the main coagulation factor - FX in human endometrial cancer tissue.
MATERIALS AND METHODS: Immunohistochemical analysis was performed on 21 endometrial cancer specimens employing antibodies against ZPI, PZ and FX.
RESULTS: Endometrial cancer cells showed a strong expression of ZPI and PZ and medium expression of FX. Normal endometrial tissue showed no expression of ZPI, PZ or FX.
CONCLUSION: Strong expression of PZ and ZPI in endometrial cancer cells suggests a role of these proteins in endometrial cancer. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Protein Z; coagulation inhibitor; endometrial cancer; factor X; protein Z-dependent protease inhibitor

Mesh:

Substances:

Year:  2019        PMID: 31028196      PMCID: PMC6559914          DOI: 10.21873/invivo.11538

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  2 in total

1.  PROZ May Serve as a Prognostic Biomarker for Early Hepatocellular Carcinoma.

Authors:  Xiaocong Jiang; Ting Song; Xiuhua Pan; Xinyu Zhang; Yuhong Lan; Li Bai
Journal:  Int J Gen Med       Date:  2021-08-06

2.  [Identification of Candidate Biomarkers for EGFR-T790M Drug-resistant 
Gene Mutation in Advanced Lung Adenocarcinoma].

Authors:  Lijuan Chen; Li Shan; Tingting Yu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-11-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.